🇺🇸 FDA

Intelligence · Clinical Pipeline

Chongqing Precision Biotech Pipeline

All ClinicalTrials.gov programs at Chongqing Precision Biotech — phase, modality, and trial IDs.

Programs
109

Quick answer

Chongqing Precision Biotech has 109 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.

  1. 1.0mg/kg/day PRAX-562

    Chongqing Precision Biotech Co., Ltd

    Developmental and Epileptic Encephalopathy 1

    phase 3 small molecule active

    1 trial

  2. 18F fluciclovine

    Chongqing Precision Biotech Co., Ltd

    Brain Metastases

    phase 3 small molecule completed

    2 trials

  3. 1mg elsunersen

    Chongqing Precision Biotech Co., Ltd

    Epileptic Encephalopathy

    phase 3 small molecule active

    1 trial

  4. 20mg/day PRAX-628 for 6 weeks then 30mg/day PRAX-628 for remaining 6 weeks

    Chongqing Precision Biotech Co., Ltd

    Focal Seizure

    phase 3 small molecule active

    1 trial

  5. 40 mg/day vormatrogine for 12 weeks

    Chongqing Precision Biotech Co., Ltd

    Focal Epilepsy

    phase 3 small molecule active

    1 trial

  6. 60 mg ulixacaltamide

    Chongqing Precision Biotech Co., Ltd

    Essential Tremor

    phase 3 small molecule active

    1 trial

  7. Early Vasopressin

    Chongqing Precision Biotech Co., Ltd

    Septic Shock

    phase 3 small molecule active

    1 trial

  8. ICT-107

    Chongqing Precision Biotech Co., Ltd

    Glioblastoma Multiforme

    phase 3 mab completed

    2 trials

  9. PRAX-114

    Chongqing Precision Biotech Co., Ltd

    Major Depressive Disorder

    phase 3 small molecule completed

    1 trial

  10. PRAX-222

    Chongqing Precision Biotech Co., Ltd

    Voltage-gated sodium channel type II alpha subunit (SCN2A) developmental and epileptic encephalopathy (DEE)

    phase 3 small molecule active

    1 trial

  11. PRAX-562

    Chongqing Precision Biotech Co., Ltd

    SCN2A Encephalopathy

    phase 3 small molecule active

    1 trial

  12. PRAX-628, PRAX-628, PRAX-628, PRAX-628

    Chongqing Precision Biotech Co., Ltd

    Focal onset seizures or primary generalized tonic-clonic seizures.

    phase 3 small molecule active

    1 trial

  13. PRAX-628, PRAX-628, Placebo for PRAX-628, PRAX-628

    Chongqing Precision Biotech Co., Ltd

    Focal Epilepsy

    phase 3 small molecule active

    1 trial

  14. Placebo for PRAX-628, PRAX-628

    Chongqing Precision Biotech Co., Ltd

    Focal Epilepsy

    phase 3 small molecule active

    1 trial

  15. vormatrogine

    Chongqing Precision Biotech Co., Ltd

    Epilepsy, Tonic-Clonic

    phase 3 small molecule active

    1 trial

  16. 10 mg PRAX-114

    Chongqing Precision Biotech Co., Ltd

    Major Depressive Disorder

    phase 2 small molecule completed

    1 trial

  17. 10 mg PRAX-114, 20 mg PRAX-114, and Placebo

    Chongqing Precision Biotech Co., Ltd

    Essential Tremor

    phase 2 small molecule terminated

    1 trial

  18. 100 mg PRAX-944

    Chongqing Precision Biotech Co., Ltd

    Essential Tremor

    phase 2 small molecule completed

    1 trial

  19. 30mg PRAX-628

    Chongqing Precision Biotech Co., Ltd

    Focal Onset Seizure

    phase 2 small molecule active

    1 trial

  20. 60 mg PRAX-114 or 40 mg PRAX-114

    Chongqing Precision Biotech Co., Ltd

    Post-traumatic Stress Disorder

    phase 2 small molecule terminated

    1 trial

  21. Atorvastatin Oral Tablet

    Chongqing Precision Biotech Co., Ltd

    Mild Cognitive Impairment

    phase 2 small molecule active

    1 trial

  22. BCMA CAR-T cells

    Chongqing Precision Biotech Co., Ltd

    Multiple Myeloma

    phase 2 mab active

    2 trials

  23. BCMA targeted prime CAR-T cells

    Chongqing Precision Biotech Co., Ltd

    Multiple Myeloma

    phase 2 mab active

    1 trial

  24. CD123 CAR-T cells

    Chongqing Precision Biotech Co., Ltd

    Leukemia

    phase 2 mab active

    2 trials

  25. CD123 targeted CAR-NK cells

    Chongqing Precision Biotech Co., Ltd

    Acute Myeloid Leukemia

    phase 2 mab active

    1 trial

  26. CD19 CAR-T cells

    Chongqing Precision Biotech Co., Ltd

    Autoimmune Diseases

    phase 2 mab active

    1 trial

  27. CD19 CAR-T cells

    Chongqing Precision Biotech Co., Ltd

    Leukemia

    phase 2 mab active

    2 trials

  28. CD19 and CD22 targeted CAR-T cells

    Chongqing Precision Biotech Co., Ltd

    Leukemia, B-cell

    phase 2 mab active

    2 trials

  29. CD19 and CD22 targeted prime CAR- T cells

    Chongqing Precision Biotech Co., Ltd

    B Cell Lymphoma

    phase 2 mab active

    1 trial

  30. CD19 and CD22 targeted prime CAR-T cells

    Chongqing Precision Biotech Co., Ltd

    B-ALL

    phase 2 mab active

    1 trial

  31. CEA CAR-T cells

    Chongqing Precision Biotech Co., Ltd

    Solid Tumor

    phase 2 mab active

    1 trial

  32. CEA-targeted CAR-T cells

    Chongqing Precision Biotech Co., Ltd

    Gastric Cancer

    phase 2 mab active

    3 trials

  33. Gemcitabine

    Chongqing Precision Biotech Co., Ltd

    Pancreatic Cancer, Adult

    phase 2 small molecule terminated

    1 trial

  34. Melphalan flufenamide (Melflufen)

    Chongqing Precision Biotech Co., Ltd

    Multiple Myeloma

    phase 2 small molecule completed

    1 trial

  35. NEO-201 in combination with pembrolizumab

    Chongqing Precision Biotech Co., Ltd

    Non Small Cell Lung Cancer

    phase 2 small molecule active

    1 trial

  36. NPC-1C/NEO-102

    Chongqing Precision Biotech Co., Ltd

    Metastatic Pancreatic Cancer

    phase 2 small molecule completed

    1 trial

  37. NY-ESO-1(TCR Affinity Enhancing Specific T cell Therapy)

    Chongqing Precision Biotech Co., Ltd

    Soft Tissue Sarcoma

    phase 2 mab active

    1 trial

  38. OPM-101

    Chongqing Precision Biotech Co., Ltd

    Advanced Melanoma

    phase 2 small molecule active

    1 trial

  39. PBCAR20A

    Chongqing Precision Biotech Co., Ltd

    Non-Hodgkin's Lymphoma, Relapsed

    phase 2 gene therapy completed

    1 trial

  40. PBGENE-DMD (IV)

    Chongqing Precision Biotech Co., Ltd

    Duchenne Muscular Dystrophy With Mutations Amenable to PBGENE-DMD

    phase 2 mab active

    1 trial

  41. PCN-101

    Chongqing Precision Biotech Co., Ltd

    Treatment Resistant Depression

    phase 2 small molecule completed

    1 trial

  42. PDI-192

    Chongqing Precision Biotech Co., Ltd

    Atopic Dermatitis

    phase 2 small molecule completed

    1 trial

  43. PDI-320

    Chongqing Precision Biotech Co., Ltd

    Rosacea

    phase 2 small molecule active

    1 trial

  44. PRAX-222 - Initial Dose

    Chongqing Precision Biotech Co., Ltd

    SCN2A-DEE

    phase 2 small molecule active

    1 trial

  45. PRAX-628

    Chongqing Precision Biotech Co., Ltd

    Focal onset seizures or primary generalized tonic-clonic seizures

    phase 2 small molecule active

    1 trial

  46. Part A: 20 and 40 mg PRAX-944

    Chongqing Precision Biotech Co., Ltd

    Essential Tremor

    phase 2 small molecule completed

    1 trial

  47. delolimogene mupadenorepvec

    Chongqing Precision Biotech Co., Ltd

    Malignant Melanoma

    phase 2 gene therapy completed

    1 trial

  48. donor-derived NK cell infusion

    Chongqing Precision Biotech Co., Ltd

    Non-small Cell Lung Cancer

    phase 2 mab active

    1 trial

Frequently asked questions

How many pipeline programs does Chongqing Precision Biotech have?

109 published programs are linked to this sponsor in our ClinicalTrials.gov index.

Is this the complete company pipeline?

This hub lists all published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.

Data attribution: Data sources · All pipeline programs

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.